Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Biomarker is a biological molecule which is found in blood, other body fluids, or tissues, and signals a normal or abnormal process, or of a condition or disease including cancer. The biomarker can be used for the evaluation of cancer patients for wide range of applications including estimating risk of disease, screening for occult primary cancers, distinguishing benign from malignant findings or one type of malignancy from another, determining prognosis and prediction for patients who have been diagnosed with cancer, and monitoring status of the disease, either to detect recurrence or determine response or progression to therapy. Owing to their ability to enhance the clinical outcomes in cancer patients, pharmaceutical companies have actively invest in this sector.
In last few years, the entrances of antibody therapeutics have greatly revolutionized the paradigm of cancer treatment. Due to their high specificity and efficiency, these have contributed to significant share in the targeted cancer therapy market. Despite their promising results, few patients develop resistance and some do not respond to the therapy, thus surging the demand for the development of biomarkers. Till date, several biomarkers have been approved which are used to predict the outcome of the cancer antibody therapy.
In addition to this, researchers have also initiated several clinical trials to evaluate novel biomarkers to antibody therapy. Currently, more than 500 clinical trials are ongoing which are evaluating the role of biomarkers in cancer patients. For instance, a recent study demonstrates that germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types. Apart from this, in patients with non-small cell lung cancer treated with immune checkpoint inhibitors, tumor mutational burden (TMB) has found to be predictive potential.
Recently, artificial intelligence has also been introduced into the market owing to advances in computational algorithms, the availability of high-performance computing hardware, and the assembly of large community-based databases. The pharmaceutical companies are increasingly utilizing artificial intelligence to advance the discovery of biomarker discovery. For instance, Taiwan government launched its new Artificial Intelligence (AI) hub. The island nation has identified the capabilities of AI to increase the productivity and efficiency of various industries. Hence, the government decided to adopt multiple measures to support industrial AI research and development. Apart from this, Chinese team of scientists combined radiomic data from preoperative positron emission tomography (PET) and CT images in patients with early-stage uterine cervical squamous cell carcinoma. Then, they used AI algorithms to develop a prognostic signature capable of predicting disease-free survival.
The increasing preference for antibody based therapies for the treatment of patients suffering from different types of malignant cancers is one of the major factors driving the growth of the market. Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process. The strategic alliances for biomarker applications in large-stage clinical trials are fueling the growth of this market during the forecast period. The major key players in the market include Roche, Abbott Laboratories, GlaxoSmithKline, Eli Lilly, Pfizer, Illuminia, and others. Further, rise in awareness programs for early diagnosis of cancer has also led to increase in demand of profiling technologies.
The report provides comprehensive analysis of the cancer antibodies biomarker market. This report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on changing market trends, market players and leading products. This chapter also covers mergers and acquisitions and other collaborations or partnerships that are expected to shape the industry.